secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0000950103-22-011927
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen agrees to sell Trans Ova Genetics to URUS for $170M upfront cash plus $10M earn-out
--------------------------------------------------------------------------------

- Total consideration up to $180M: $170M cash at closing plus $10M earn-out based on 2022-2023 performance.
- Transaction expected to close in Q3 2022, subject to HSR clearance and other customary conditions.
- Proceeds will be used to pay senior convertible notes due July 2023 and fund healthcare pipeline.
- Divestiture completes strategy to focus exclusively on healthcare, shedding the animal reproductive technologies unit.
- Rabo Securities acted as financial advisor; Davis Polk provided legal support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322011927/0000950103-22-011927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322011927/dp176668_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-011927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer